Spruce Biosciences, Inc.

SPRB · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.4%

Institutions76.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$4.90M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$36.51M	-$56.15M	-$42.07M	-$29.42M
Operating income as a percentage of revenue.	–	-1145.9%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$38.97M	-$53.04M	-$42.29M	-$29.54M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-50.83	$-1.29	$-1.81	$-4.93
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-50.83	$-1.29	–	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$48.91M	$38.75M	$42.75M	$157.15M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$53.02M	$45.21M	$126.49M	–
All of the company's interest-bearing borrowings, short and long term combined.	$0	$1.75M	$4.88M	$4.48M
Everything the company owes — debt, unpaid bills, and other obligations.	$10.51M	$16.39M	$15.12M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$42.52M	$28.82M	$111.37M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$33.33M	-$55.96M	-$35.88M	-$27.52M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	$0	$93000	$74000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	-$55.96M	-$35.97M	-$27.59M

	You	Peer avg
Revenue Growth	–	-4.4%
ROE	-106.0%	-215.5%

Spruce Biosciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison